This phase II trial is assessing the benefits of using a targeted therapy (cemiplimab) in combination with a biological therapy (RP1) to treat patients with advanced or metastatic cutaneous squamous cell carcinoma.
This trial is treating patients with Cutaneous Squamous Cell Carcinoma.
This is a systemic therapy.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Patients eligible to participate in this trial will receive either Cemiplimab alone, or in combination with RP1. Cemiplimab will be intravenously administered every 3 weeks, while RP1 will be administered as an direct injection into the tumour every 3 weeks.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More